Needham reiterated coverage of Hologic with a rating of Hold
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/7/2025 | $78.00 | In-line → Outperform | Evercore ISI |
| 8/18/2025 | $80.00 | Hold → Buy | Argus |
| 8/6/2025 | $87.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 7/9/2025 | $80.00 | Neutral → Buy | Citigroup |
| 5/27/2025 | Hold | Needham | |
| 3/3/2025 | Buy → Hold | Argus | |
| 2/6/2025 | $80.00 → $75.00 | Outperform → Market Perform | Leerink Partners |
| 2/3/2025 | Buy → Hold | Needham |
DEFA14A - HOLOGIC INC (0000859737) (Filer)
DEFA14A - HOLOGIC INC (0000859737) (Filer)
DEFA14A - HOLOGIC INC (0000859737) (Filer)
For Immediate Release: October 29, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA responded to objections on the agency’s final rule that removed the authorized food contact uses of most phthalates because industry abandoned these uses. The FDA evaluated the objections and concluded that they did not provide a basis for mod
For Immediate Release: February 02, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a safety communication to warn consumers, health care providers, and health care facilities not to use certain Cardinal Health Monoject luer-lock and enteral syringes. Dimensional changes made to the syringes, when used with syringe pump
Hologic Stockholders to Receive $76 per Share in Cash Plus a Contingent Value Right of up to $3 per Share Payable Upon Achieving Certain Revenue Milestones Represents 46% Premium to Hologic's Closing Price on Last Trading Day Prior to Media Reports of Possible Transaction Transaction Includes Significant Minority Investments from ADIA and GIC Transaction Will Help Hologic Strengthen its Leadership in Women's Health and Accelerate Growth Hologic, Inc. (NASDAQ:HOLX) today announced that it has entered into a definitive agreement to be acquired by funds managed by Blackstone ("Blackstone") and TPG in a transaction valued at up to $79 per share, representing an enterprise value of up to
NetworkNewsWire Editorial Coverage NEW YORK, Oct. 21, 2025 /PRNewswire/ -- Artificial intelligence (AI) is making inroads into every corner of medical technology, perhaps none more urgently than imaging. In breast cancer detection, where early diagnosis can mean the difference between life and death, AI-enhanced modalities present a chance to leap beyond the limits of mammography, tomosynthesis, and MRI. Globally, breast cancer remains one of the most common cancers in women. According to the World Health Organization (WHO), more than 2.3 million women were diagnosed with breast cancer in 2022, and approximately 670,000 women died from the disease globally. In the United States, the American
Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2025 on Monday, November 3, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing 800-330-6710 (in the United States and Canada) or +1 312-471-1353 (for international callers) and referencing access code 5756948. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. Hologic will provide a live and webcast replay of the call on the Company's website at investors.hologic.
4 - HOLOGIC INC (0000859737) (Issuer)
4 - HOLOGIC INC (0000859737) (Issuer)
4 - HOLOGIC INC (0000859737) (Issuer)
4 - HOLOGIC INC (0000859737) (Issuer)
Evercore ISI upgraded Hologic from In-line to Outperform and set a new price target of $78.00
Argus upgraded Hologic from Hold to Buy and set a new price target of $80.00
RBC Capital Mkts upgraded Hologic from Sector Perform to Outperform and set a new price target of $87.00
Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi
Renowned industry experts join to aid in preparation around premarket approval for FirstSight SUNNYVALE, Calif., April 6, 2023 /PRNewswire-PRWeb/ -- CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer screening blood test, today announced the appointment of Stanley N. Lapidus (Stan) as an advisory board member and Ronnie (Ron) Andrews as an independent board member. The announcement comes only one month after CellMax Life expanded its GI advisory board with luminaries in the GI arena. "Both Stan and Ron are pioneers in the diagnostics industry, with unique perspectives and proven track records of success," said Atul Sharan, CEO of CellMax Life. Stan is one of t
MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders. "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics. "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo
Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2025 on Monday, November 3, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing 800-330-6710 (in the United States and Canada) or +1 312-471-1353 (for international callers) and referencing access code 5756948. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. Hologic will provide a live and webcast replay of the call on the Company's website at investors.hologic.
– Revenue of $1,023.8 Million Exceeds Guidance – – Company Reports GAAP Diluted EPS of $0.86; Non-GAAP Diluted EPS of $1.08 Exceeds Guidance – – In Fourth Quarter, Company Remains on Track for Solid Revenue Growth and Faster Non-GAAP EPS Growth – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal third quarter ended June 28, 2025. "We are pleased to have delivered revenue and non-GAAP earnings growth in the third quarter that exceeded our guidance ranges," said Stephen P. MacMillan, the Company's Chairman, President and Chief Executive Officer. "And we made great progress toward returning to better top- and bottom-line growth in the fourth qua
Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2025 on Wednesday, July 30, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (866) 400-0049 (in the United States and Canada) or +1 (313) 209-4906 (for international callers) and referencing access code 5212316. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. Hologic will provide a live and webcast replay of the call on the Company's website at investors.holog
SC 13G/A - HOLOGIC INC (0000859737) (Subject)
SC 13G - HOLOGIC INC (0000859737) (Subject)
SC 13G/A - HOLOGIC INC (0000859737) (Subject)